Expression and clinical significance of IL-17 and its receptor in bacterial pneumonia before and after treatment

IL-17及其受体在细菌性肺炎治疗前后的表达及其临床意义

阅读:2

Abstract

OBJECTIVES: To investigate the expression of serum Interleukin-17 (IL-17) and its receptor IL-17R in patients with bacterial pneumonia and their diagnostic value for severe bacterial pneumonia. METHODS: In this retrospective analysis, 172 patients diagnosed with bacterial pneumonia were included and categorized into the severe (n = 61) and non-severe (n = 111) groups. Serum concentrations of IL-17, IL-17R, procalcitonin (PCT), and high-sensitivity C-reactive protein (hs-CRP) were measured using ELISA upon admission and after antibiotic treatment. ROC curves were drawn to assess the diagnostic performance of influencing factors, correlation analyses were performed to explore relationships among biomarkers, and logistic regression to identify independent risk factors. RESULTS: Before treatment, patients with severe bacterial pneumonia demonstrated significantly higher levels of IL-17, IL-17R, PCT, and hs-CRP compared to non-severe patients (all P < 0.001). All biomarkers decreased significantly after treatment in severe group (all P < 0.05). IL-17 and IL-17R showed good accuracy in identifying severe disease (AUC = 0.808 and 0.777, respectively) and were positively correlated with PCT and hs-CRP (all P < 0.05). Multivariate analysis identified IL-17, IL-17R, PCT, and hs-CRP as independent risk factors for severe bacterial pneumonia. CONCLUSIONS: IL-17 and IL-17R are elevated in bacterial pneumonia, demonstrating close association with disease severity and conventional markers. Their decline after treatment indicates therapeutic effectiveness. These cytokines show diagnostic potential and could help monitor disease progression and treatment response. Future research should confirm these findings in larger cohorts and investigate their interactions with other inflammatory pathways.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。